The French-Canadian validation of a disease-specific,patient-reported outcome measure for lupus

Abstract

Objectives

The objective of this paper is to perform the cross-cultural validation of the French version of the LupusPRO, a disease-targeted patient-reported outcome measure, among systemic lupus erythematosus (SLE) patients in Canada.

Methods

The French version of the LupusPRO and the MOS SF-36 were administered; demographic, clinical and serological characteristics were obtained. Disease activity (SELENA-SLEDAI and the Lupus Foundation of America definition of flare) and damage (SLICC/ACR SDI) were assessed. Physician disease activity and damage assessments were ascertained using visual analog scales. Internal consistency reliability (ICR), test-retest reliability (TRT), convergent and discriminant validity (against corresponding domains of the SF-36), criterion validity (against disease activity, damage or health status) and known group validity were tested.

Results

A total of 99 French-Canadian SLE patients participated (97% women, mean (SD) age 45.2 (14.5) years). The median (IQR) SELENA-SLEDAI and SDI were 3.5 (6.0) and 1.0 (2.0), respectively. The ICR of the LupusPRO domains ranged from 0.81 to 0.93 (except for lupus symptoms, procreation and coping), while TRT ranged from 0.72 to 0.95. Convergent and discriminant validity, criterion validity and known group validity against disease activity, damage and health status measures were observed. Confirmatory factor analysis showed a good fit.

Conclusion

The LupusPRO has fair psychometric properties among French-Canadian patients with SLE.

Keywords

Systemic lupus erythematosus quality of life self-assessment

Get full access to this article

View all access options for this article.

References

Jolly

. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005; 32: 1706–1708.

Thakkar

Mikolaitis

Block

Jolly

. Caregiver burden is associated with worse dyadic relationship and health outcomes in lupus? Arthritis Rheum 2011; 63(Suppl): 557.

Guidance for industry. Systemic Lupus Erythematosus—Developing Medical Products for Treatment, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072063.pdf (accessed June 2011).

Jolly

Pickard

Block

. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012; 42: 56–65.

Toloza

Jolly

Alarcón

. Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: Cross-cultural issues. Curr Rheumat Rep 2010; 12: 237–249.

Bourré-Tessier

Clarke

Mikolaitis-Preuss

. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Canada. J Rheumatol 2013; 40: 1327–1333.

Navarra

Tanangunan

Mikolaitis-Preuss

Kosinski

Block

Jolly

. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus 2013; 22: 262–267.

Jolly

Toloza

Block

. Spanish LupusPRO: Cross-cultural validation study for lupus. Lupus 2013; 22: 431–436.

Kaya

Goker

Cura

. Turkish LupusPRO: Cross-cultural validation study for lupus. Clin Rheumatol. Epub ahead of print 11 August 2013.

10.

Guillemin

Bombardier

Beaton

. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417–1432.

11.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

12.

Ware

The SF-36 Health survey. In: Spiker

(ed). Quality of life and pharmacoeconomics in clinical trials, Philadelphia: Lippincott-Raven, 1996, pp. 337–345.

13.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

14.

Ruperto

Hanrahan

Alarcón

. International consensus for a definition of disease flare in lupus. Lupus 2011; 20: 453–462.

15.

Gladman

Ginzler

Goldsmith

. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

16.

Aday

. Designing and conducting health surveys, 2nd ed. San Francisco, CA: Jossey-Bass Inc, a Wiley Company, 1996.

17.

Di Fabio

. Comparing clinical assessments: Which is better? In:Essentials of rehabilitation research: A statistical guide to clinical practice, Philadelphia: F.A. Davis Company, 2013, pp. 60–61.

18.

Bentler

. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equa Model 1999; 6: 1–55.

19.

Mplus user's guide computer program, Los Angeles: Muthén & Muthén, 2001.

20.

Hays

Anderson

Revicki

. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993; 2: 441–449.

21.

Strand

Gladman

Isenberg

Petri

Smolen

Tugwell

. Endpoints: Consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000; 9: 322–327.

22.

Statistics Canada: Population by knowledge of official languages, 2006 census. http://www.statcan.gc.ca/tables-tableaux/sum-som/cst01/dem015-cng.htm (accessed June 2011).

23.

Devilliers

Amoura

Besancenot

. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012; 51: 1906–1915.

24.

Leong

Kong

Thong

. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005; 44: 1267–1276.

25.

Doward

McKenna

Whalley

. The development of the L-QoL: A quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2008; 59: 84–88.

26.

McElhone

Abbott

Shelmerdine

. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 972–979.

27.

Jolly

Cornejo

Mikolaitis

Block

. LupusPRO and responsiveness to changes in health status and disease activity over time (abstract). Arthritis Rheum 2011; 63: S898.

28.

Devilliers

Garris

Kosinski

Jolly

. Lupus Impact Tracker is responsive to changes in Physician Assessed Disease Status by Systemic Lupus Erythematosus Responder Index (abstract). Arthritis Rheum 2013; 65: S1083.

29.

Jolly

Kosinski

Toloza

. Equivalence of various language versions of lupus specific patient reported outcomes measure (LupusPRO) (abstract). Arthritis Rheum 2012; 64: S607.